Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

Anti-B7-H3 ADCs tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates versus topotecan in relapsed small-cell lung cancer.

• Why it matters: Relapsed small-cell lung cancer has limited effective options, creating a need for therapies that improve survival and tumor response beyond standard treatment with topotecan.
• What they did: Two separate phase III trials compared each anti-B7-H3 ADC to topotecan, while a third trial tested pumitamig plus elfetabart drozuntecan in SCLC across lines of therapy and doses.
• The result: The phase III results show significant efficacy gains over topotecan, and the bispecific plus anti-B7-H3 ADC combination demonstrated encouraging early efficacy in SCLC.

AI summary of the abstract · may contain errors · not medical advice · read the paper.